Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
about
Bioidentical hormones for menopausal hormone therapy: variation on a themeRole of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidenceEthical problems with bioidentical hormone therapyPharmacology of estrogens and progestogens: influence of different routes of administrationTransdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics.Perimenopausal and Postmenopausal Health."Extracts from "Clinical evidence": Menopausal symptoms.Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.Progesterone and bone: actions promoting bone health in women.Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.Hot flashes in breast cancer survivors.Hot flashes: a review of pathophysiology and treatment modalities.Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies.Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us?Non-estrogenic approaches for the treatment of climacteric symptoms.Bioidentical hormone therapy: Nova Scotia pharmacists' knowledge and beliefsMenopausal hot flushes revisited.A practitioner's toolkit for managing the menopause.Oestrogen replacement in postmenopausal women.Effect of urea and pantothenol on the permeation of progesterone through excised rat skin from polymer matrix systems.Evaluation of progesterone permeability from supercritical fluid processed dispersion systems.A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women.Preparation and characterization of progesterone dispersions using supercritical carbon dioxide
P2860
Q24643351-F8A9C89A-23F9-4C1D-8FF8-360026918B38Q24647700-36369795-1742-4BA9-AE6B-0D5B73A24130Q28260821-9C40B4D6-5F65-4D50-B411-1328513894C8Q28268346-32F47F3B-7B46-48A0-A5AE-F7A42B4AD027Q31136140-20457230-B8AC-409E-9097-4144D4E3291FQ33206403-A2ADBA8B-A51A-4D42-B1AD-0576B0822F88Q33803356-DF7177AF-ADF3-431F-8F37-763CBD620B05Q33926091-D7641ABD-3870-432F-BAEF-44AA3EB31F6BQ34261512-1A314FEC-0F02-4319-A16C-9304C5B07801Q34272132-6D63695F-F45E-45A4-B763-9CDDC9DBFE9EQ34447997-5A6A8E7C-DEB0-4ABC-B814-569CFA8FFEC0Q35216824-04A92355-AE8E-4DEF-A79F-853CC18F964AQ35599841-1762292E-D7FF-405A-8C49-6FFCFE59B030Q36219667-F4F93615-5F5D-4D70-97F6-1ECA0F93E5E3Q36259505-DD632136-ABE3-4A75-A7E7-D4715AB9DE68Q36946834-7023DD4B-4900-4C24-9D65-A4CAE828E310Q37190890-3A03B9DF-E58B-45C2-88E0-0448574CAA08Q37342902-2B1E03A0-20E1-4F49-8F94-9B5850C3CCFCQ38226731-274C75DA-98DD-4E99-BC5B-841980D1D31CQ38526762-7051AB0D-174E-4ABB-B0FE-BB9055D95B7DQ43541470-23D82C20-4971-4A77-B2AC-BA079C74D659Q43565035-9F800950-C1AB-4655-A42F-1F28810AD9E9Q53910450-C24C3F38-8633-44D6-83EA-E393B05988F8Q57164401-B17B97B6-BAA3-45B5-84F9-C91CBCAF2E76
P2860
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@ast
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@en
type
label
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@ast
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@en
prefLabel
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@ast
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@en
P2093
P1476
Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss.
@en
P2093
P304
P356
10.1016/S0029-7844(99)00266-5
P407
P577
1999-08-01T00:00:00Z